← All trials
NCT06495918
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2024
- Primary completion
- Jan 8, 2027
- Completion date
- Jan 8, 2027
- First posted
- Jul 11, 2024
- Last posted
- Jul 24, 2024
- Enrollment
- 825
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ocular Therapeutix, Inc.Lead sponsor
- Duke UniversityCollaborator
- California Retina ConsultantsOfficial
- FortreaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.